PAREXEL International Corporation (“PAREXEL,” “the Company,” or “we”) is a leading biopharmaceutical outsourcing services company, providing a broad range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries. Our primary objective is to provide quality solutions for managing the biopharmaceutical product lifecycle with the goal of reducing the time, risk, and cost associated with the development and commercialization of new therapies. Since our incorporation in 1983, we have developed significant expertise in processes and technologies supporting this strategy. Our product and service offerings include: clinical trials management, observational studies and patient/disease registries, data management, biostatistical analysis, epidemiology, health economics/outcomes research, pharmacovigilance, medical communications, clinical pharmacology, patient recruitment, clinical supply and drug logistics, post-marketing surveillance, regulatory and product development and commercialization consulting, health policy and reimbursement and market access consulting, medical imaging services, regulatory information management (“RIM”) solutions, ClinPhone randomization and trial supply management services (“RTSM”), electronic data capture systems (“EDC”), clinical trial management systems (“CTMS”), web-based portals, systems integration, patient diary applications, and other product development tools and services. We believe that our comprehensive services, depth of therapeutic area expertise, global footprint and related access to patients, and sophisticated information technology, along with our experience in global drug development and product launch services, represent key competitive strengths. On June 19, 2017, PAREXEL entered into an Agreement and Plan of Merger pursuant to which West Street Merger Sub Inc., a Massachusetts corporation and a wholly-owned subsidiary of West Street Parent, LLC, a Delaware limited liability company (which we refer to as Parent) and affiliate of Pamplona Capital Management, LLP, will be merged with and into us, with PAREXEL surviving as a subsidiary of West Street Parent, LLC, which we refer to as the merger will acquire all of the outstanding shares of PAREXEL for $88.10 per share in cash in a transaction valued at approximately $5.5 billion including PAREXEL’s net debt. Consummation of the merger is subject to various customary conditions including adoption of the merger agreement by the Company’s stockholders and receipt of required regulatory approvals, the closing is expected to be completed late in the third or early in the fourth quarter of calendar year 2017.
Company profile
Ticker
PRXL
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Syneos Health • Medpace • Incyte • Zymergen • OmniAb • SomaLogic ...
SEC CIK
Corporate docs
IRS number
42776269
Latest filings (excl ownership)
15-12G
Securities registration termination
10 Oct 17
25-NSE
Exchange delisting
29 Sep 17
8-K
Pamplona Capital Management Completes Acquisition
29 Sep 17
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Sep 17
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Sep 17
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Sep 17
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Sep 17
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Sep 17
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Sep 17
8-K
Parexel International Receives Shareholder Approval
18 Sep 17
Latest ownership filings
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|